DB Ashbourne Limited has been acquired by Ethypharm S.A
The shareholder of DB Ashbourne Limited (DBA) has sold the company to Ethypharm S.A. for an undisclosed consideration.
DBA currently markets and supplies a range of prescription-only medicines to the UK market, generating significant savings for the National Health Service (NHS) and has an exciting pipeline of products in development which will be supplemented with a wide range of additional products from the Ethypharm pipeline.
Ethypharm S.A. is a France-based company engaged in developing, manufacturing and licensing pharmaceutical products. Through the acquisition of DBA, Ethypharm continues to implement its strategy to develop a direct commercial presence in key territories in Europe to market central nervous system products, with a particular focus on pain and innovative treatments for addictions. DBA provides a pivotal platform to generate revenues in the important UK market and this acquisition, along with the deployment of its own commercial operations in France and Germany, will generate a large turnover.
“I am delighted to welcome the DBA team to the Ethypharm group. The acquisition of DBA is a significant step forward for us. The know-how and expertise of both companies are totally complementary and synergistic and DBA offers a great platform to launch products from our own pipeline,” declared Hugues Lecat, CEO of Ethypharm.
Oaklins Cavendish, based in the UK, advised the seller in this transaction.
Talk to the deal team
Related deals
Dimainvest S.r.l. has launched a voluntary public tender offer for Shedir Pharma Group S.p.A.
Dimainvest S.r.l. has initiated a voluntary public tender offer for the shares of Shedir Pharma Group S.p.A.
Learn moreAcapo AS has been acquired by Longship AS
Oslo-based intellectual property advisory firm Onsagers, supported by Longship since May 2024, has acquired Acapo AS. By combining decades of expertise and global reach, this strategic acquisition unites two of Norway’s most reputable IP firms, enabling them to offer a comprehensive range of solutions in patents, trademarks and IP strategy. This milestone strengthens their position in building a best-in-class network for strategic IP management, marking a key step in their continued growth.
Learn moreAfric Phar has been acquired by Pharma Capital
Pharma Capital S.A. has acquired a significant stake in the Moroccan pharmaceutical group Afric Phar, which includes leading companies Afric Phar, Pharmis and Partner Lab, from the Chaoui family, in one of the largest transactions in the Moroccan pharmaceutical sector.
Learn more